[A21-84] Dostarlimab (endometrial cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 02.12.2021
Project no.:
A21-84
Commission:
Commission awarded on 16.06.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with mismatch repair deficient/microsatellite instability-high recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-139 | Dostarlimab (endometrial cancer) - Addendum to commission A21-84 | Commission completed |
| A23-143 | Dostarlimab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| G21-31 | Dostarlimab (endometrial cancer) - Second addendum to commission A21-84 | Commission completed |
Federal Joint Committee (G-BA)
2021-12-02 A G-BA decision was published.